Serum testosterone concentrations and outcomes in hemodialysis patients enrolled in the EVOLVE trial

• Published in: Nephrology, dialysis, transplantation dialysis, transplantation, 2023-05, Vol.38 (6), p.1519-1527
• Main Authors: Nilsson, Erik, Stenvinkel, Peter, Liu, Sai, Stedman, Margaret R, Chertow, Glenn M, Floege, Jürgen
• Format: Article
• Language: English
• Subjects: Cardiovascular Diseases - etiology; Cinacalcet - therapeutic use; Female; Humans; Male; Medicin och hälsovetenskap; Renal Dialysis - adverse effects; Testosterone
• ISSN: 0931-0509; 1460-2385; 1460-2385
• DOI: 10.1093/ndt/gfac278

ABSTRACT Background Hypogonadism is common in end-stage kidney disease and may contribute to morbidity and mortality. Methods Using data from the randomized controlled Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) trial of cinacalcet, we analyzed the associations of total testosterone, free testosterone and sex hormone–binding globulin (SHBG) serum concentrations with mortality and major cardiovascular events in 1692 men and 1059 women receiving hemodialysis. We also describe the effect of cinacalcet treatment on serum concentrations of testosterone. Results Among men, lower serum free testosterone [odds ratio (OR) 0.18, 95% confidence interval (CI) 0.04–0.82, P = .026] and higher SHBG (OR 1.05 per 10 nmol/L, 95% CI 1.01–1.10, P = .012), but not total testosterone, were associated with higher risk of death or cardiovascular event. Only SHBG was associated with all-cause mortality (OR 1.07 per 10 nmol/L, 95% CI 1.02–1.12, P = .0073). Among women, neither total nor free testosterone, nor SHBG were associated with outcomes. We found no statistically significant effect of cinacalcet treatment on SHBG, free or total testosterone. Conclusions Lower free testosterone and higher SHBG in serum are associated with higher risk of death or cardiovascular event in men undergoing chronic hemodialysis.